---
title: "Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283723406.md"
description: "Hepion Pharmaceuticals has raised $700,000 through a private placement of 17.5 million shares at $0.04 each. The transaction, which closed on April 21, 2026, was conducted under Regulation D, Section 4(a)(2) and Rule 506(b). The shares are unregistered and subject to resale restrictions under U.S. securities laws. This move aims to strengthen the company's liquidity through equity financing."
datetime: "2026-04-22T20:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283723406.md)
  - [en](https://longbridge.com/en/news/283723406.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283723406.md)
---

# Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04

Hepion Pharmaceuticals entered into securities purchase agreements with accredited investors for a private placement of 17,500,000 shares of common stock at $0.04 per share, generating gross proceeds of $700,000. The transaction, which closed on April 21, 2026, was conducted under Section 4(a)(2) and Rule 506(b) of Regulation D. The shares are unregistered and subject to resale restrictions under U.S. securities laws.

**Agreement details:**

-   **Agreement type**: Securities purchase agreements for private placement of common stock
-   **Counterparty**: Accredited investors
-   **Signed / Effective**: Apr 21 2026 / same
-   **Reason**: Strengthen liquidity through equity financing

Original SEC Filing: Hepion Pharmaceuticals, Inc. \[ HEPA \] - 8-K - Apr. 22, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [HEPA.US](https://longbridge.com/en/quote/HEPA.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)